Zlatanovic, Petar (57201473730)Petar (57201473730)ZlatanovicJovanovic, Aleksa (57216047949)Aleksa (57216047949)JovanovicTripodi, Paolo (57191963001)Paolo (57191963001)TripodiDavidovic, Lazar (7006821504)Lazar (7006821504)Davidovic2025-06-122025-06-122023https://doi.org/10.1007/s00268-022-06829-xhttps://www.scopus.com/inward/record.uri?eid=2-s2.0-85142421817&doi=10.1007%2fs00268-022-06829-x&partnerID=40&md5=4822a71e3fbaf48f9545878d3d356ba3https://remedy.med.bg.ac.rs/handle/123456789/2811Introduction: The aim of this systematic review and network meta-analysis was to compare the short-term results of fenestrated endovascular repair (FEVAR), chimney endovascular repair (ChEVAR), and open surgery (OS) for patients with juxta/pararenal abdominal aortic aneurysms (JAAA/PAAA). Materials and methods: MEDLINE, SCOPUS, and Web of Science were searched from inception to 1 July 2022. Any comparative studies investigating the results of two or three treatment strategies (ChEVAR, FEVAR, or OS) on clinical outcomes for patients with JAAA/PAAA were included. Analysed outcomes were 30-day mortality, acute kidney injury (AKI), major adverse cardiovascular events (MACE), and bowel ischaemia (BI). Results: A total of 22 studies with 8853 patients were included in the analysis. FEVAR (OR = 0.58, 95%CrI 0.36–0.82) and ChEVAR (OR = 0.56, 95%CrI 0.28–1.02) were associated with lower 30-day mortality than OS. FEVAR (OR = 0.54, 95%CrI 0.33–0.85) was associated with lower risk of AKI than OS. FEVAR (OR = 0.43, 95%CrI 0.20–0.89) and ChEVAR (OR = 0.34, 95%CrI 0.10–0.93) compared to OS were associated with lower rates of BI. FEVAR (OR = 0.67, 95%CrI 0.49–0.90) and ChEVAR (OR = 0.61, 95%CrI 0.35–1.02) were associated with lower 30-day MACE risk than OS. FEVAR was associated with a higher rate of SCI compared to OS (OR = 4.90, 95%CrI 1.55–19.17). Conclusion: We found a clear benefit for FEVAR and ChEVAR versus OS in terms of reduced 30-day mortality, BI, and MACE, as well as AKI for FEVAR. This suggests that higher-risk patients might benefit from endovascular treatment of JAAA/PAAA; however, should be applied in clinical practice with caution, since long-term outcomes were outside of the scope of this review. © 2022, The Author(s) under exclusive licence to Société Internationale de Chirurgie.